retatrutide phase 2 trial type 2 diabetes results 2024 Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first 3 for treatment of New Kind of Diabetes Drug

Gastric Emptying Slows down the rate at which the stomach empties its contents into the intestines, which helps reduce the rate at which sugar is absorbed into the bloodstream

The gastric emptying effect is dose-dependent and peaks during the first 48 to 72 hours after each weekly injection

However, available retatrutide data in type 2 diabetes indicate that triple agonism can improve glycemic control despite glucagon receptor activity

Tell your doctor immediately if you notice any change in your vision particularly sudden, painless visual loss or a new visual field defect

Good hygiene methods can prevent bleeding gums during this time

Net Weight: 125g